Hilton Worldwide has been granted a patent for a method of treating keloids using hypoxia-inducible factor-1 (HIF-1) inhibiting compounds. The method involves administering a therapeutically effective amount of the compound to induce cell death in keloids. GlobalData’s report on Hilton Worldwide gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Hilton Worldwide, Location-based parallel gaming was a key innovation area identified from patents. Hilton Worldwide's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Treating keloids using hif-1 inhibiting compounds
A recently granted patent (Publication Number: US11672797B2) discloses a method for treating keloids in human subjects. The method involves administering a therapeutically effective amount of a hypoxia-inducible factor-1 (HIF-1)-inhibiting compound, which has been determined through an assay to induce cell death in keloids. The patent claims that the HIF-1-inhibiting compound can be selected from a group of compounds including N,N'-(Dithiodi-2,1-ethanediyl)bis[2,5-dichlorobenzenesulfonamide (KC7F2), 2-(4-((3r,5r,7r)-adamantan-1-yl)phenoxy)-1-(4-methylpiperazin-1-yl)ethan-1-one (IDF-11774), (S)-4-(2-amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline oxide dihydrochloride (PX-478), and their pharmaceutically acceptable salts.
The method can also involve the administration of a glycolysis inhibitor, specifically 2-deoxyglucose (2-DG), in addition to the HIF-1-inhibiting compound. The patent further claims a method for inducing cell death in keloids by directly contacting the keloids with a HIF-1-inhibiting compound in an effective amount determined through an assay. Similar to the previous method, this method can also involve the use of a glycolysis inhibitor, such as 2-DG, to enhance the induction of cell death in keloids.
The patent emphasizes that the HIF-1-inhibiting compound blocks the ability of HIF-1a to form a holoprotein, which is believed to play a role in the development and progression of keloids. By inhibiting HIF-1a, the compound aims to induce cell death in keloids, potentially leading to the reduction or elimination of keloid tissue.
Overall, this granted patent presents methods for treating keloids by administering HIF-1-inhibiting compounds and potentially combining them with glycolysis inhibitors. The patent claims that these methods can effectively induce cell death in keloids, offering a potential therapeutic approach for the treatment of keloid scars in human subjects.